Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CONMED CorpCNMD · Entity 4691 | Director | June 01, 2026 | June 03, 2026 |
| Elevance Health, Inc.ELV · Entity 2934 | EVP & CFO | October 02, 2026 | October 06, 2026 |
| MOODYS CORP /DE/MCO · Entity 386 | EVP & Chief Financial Officer | August 07, 2023 | August 08, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CONMED Corp
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 820 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 668 · Balance 820 |
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-06-01 | Direct | 5,772 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Grant · Acquired 5,772 · Balance 5,772 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. |
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2035-06-02 | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-02 · Exercise / conversion · Disposed 668 · Balance 0 F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
F2: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period.
Elevance Health, Inc.
Report date October 02, 2026 · Filed October 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,503 |
Ending reported balance
After 2026-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-02 · Tax withholding · Disposed 4,161 · Balance 27,876 F1: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Row 2 · 2026-10-02 · Grant · Acquired 2,627 · Balance 30,503 F2: Represents performance based restricted share units. Restrictions lapsed on 10/2/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK.
F2: Represents performance based restricted share units. Restrictions lapsed on 10/2/2026.
MOODYS CORP /DE/
Report date August 07, 2023 · Filed August 08, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,447 |
Ending reported balance
After 2023-08-07 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2023-08-07 · Sale · Disposed 3,832 · Balance 4,447 F1: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $341.080 - $341.195. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 2 · 2023-08-07 · Exercise / conversion · Acquired 1,741 · Balance 6,188 Row 3 · 2023-08-07 · Sale · Disposed 1,741 · Balance 4,447 F2: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $341.170 - $341.280. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 4 · 2023-08-07 · Exercise / conversion · Acquired 3,470 · Balance 7,917 Row 5 · 2023-08-07 · Sale · Disposed 3,470 · Balance 4,447 F3: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $340.8701 - $341.060. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 6 · 2023-08-07 · Exercise / conversion · Acquired 714 · Balance 5,161 Row 7 · 2023-08-07 · Sale · Disposed 714 · Balance 4,447 Row 8 · 2023-08-07 · Exercise / conversion · Acquired 3,857 · Balance 8,304 Row 9 · 2023-08-07 · Sale · Disposed 3,857 · Balance 4,447 F4: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $340.8001 - $340.990. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Row 10 · 2023-08-07 · Exercise / conversion · Acquired 1,544 · Balance 5,991 Row 11 · 2023-08-07 · Sale · Disposed 1,544 · Balance 4,447 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $173.58 · Expires 2029-02-25 | Direct | 0 |
Reported balance
After 2023-08-07 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2023-08-07 · Exercise / conversion · Disposed 1,741 · Balance 0 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $280.42 · Expires 2030-02-20 | Direct | 0 |
Reported balance
After 2023-08-07 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2023-08-07 · Exercise / conversion · Disposed 3,470 · Balance 0 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $277.05 · Expires 2030-07-01 | Direct | 0 |
Reported balance
After 2023-08-07 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2023-08-07 · Exercise / conversion · Disposed 714 · Balance 0 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $276.84 · Expires 2031-02-22 | Direct | 0 |
Reported balance
After 2023-08-07 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2023-08-07 · Exercise / conversion · Disposed 3,857 · Balance 0 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $325.99 · Expires 2032-02-17 | Direct | 0 |
Reported balance
After 2023-08-07 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2023-08-07 · Exercise / conversion · Disposed 1,544 · Balance 0 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $341.080 - $341.195. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F2: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $341.170 - $341.280. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F3: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $340.8701 - $341.060. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
F4: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $340.8001 - $340.990. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 6, 2026 20:02 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 2,627 | $0.00 | $0.00 |
DisclosureSEC source: 0001748691-26-000005 · wk-form4_1791316964.xml · nonDerivative · entry 2 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,503 F2 · shares: Represents performance based restricted share units. Restrictions lapsed on 10/2/2026. Read SEC document |
| October 02, 2026 Filed Oct 6, 2026 20:02 UTC | Elevance Health, Inc. ELV · Entity 2934 | Tax withholdingCommon Stock | 4,161 | $386.43 | $1,607,935.23 |
DisclosureSEC source: 0001748691-26-000005 · wk-form4_1791316964.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,876 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:10 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRSUs (Restricted Stock Units) · Derivative | 668 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000067 · form4.xml · derivative · entry 3 Kaye Mark · CIK 0001748691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 668 shares Expires 2035-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:10 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 668 | $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000067 · form4.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 20:10 UTC | CONMED Corp CNMD · Entity 4691 | GrantRSUs (Restricted Stock Units) · Derivative | 5,772 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000067 · form4.xml · derivative · entry 2 Kaye Mark · CIK 0001748691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,772 Underlying: Common Stock · 5,772 shares Expires 2036-06-01 F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period. Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:57 UTC | Elevance Health, Inc. ELV · Entity 2934 | Tax withholdingCommon Stock | 353 | $284.03 | $100,262.59 |
DisclosureSEC source: 0001748691-26-000002 · wk-form4_1772661447.xml · nonDerivative · entry 4 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,037 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:57 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,188 | $0.00 Strike: $294.07 | $0.00 |
DisclosureSEC source: 0001748691-26-000002 · wk-form4_1772661447.xml · derivative · entry 5 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,188 Underlying: Common Stock · 25,188 shares Expires 2036-03-02 F4 · derivative.exercise_date: The option represents a right to purchase a total of 25,188 shares, and is exercisable in three annual installments, each installment of 8,396 shares, beginning on 3/2/2027, which is the one-year anniversary of the option grant date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:57 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 10,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001748691-26-000002 · wk-form4_1772661447.xml · nonDerivative · entry 3 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,390 F3 · shares: Represents restricted share units. Restrictions lapse as follows: 5,101 shares each on 3/2/2027 and 3/2/2028. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:57 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 6,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001748691-26-000002 · wk-form4_1772661447.xml · nonDerivative · entry 2 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,188 F2 · shares: Represents restricted share units. Restrictions lapse as follows: 2,125 shares on 3/2/2027, and 2,126 shares each on 3/2/2028 and 3/2/2029. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:57 UTC | Elevance Health, Inc. ELV · Entity 2934 | Tax withholdingCommon Stock | 271 | $294.07 | $79,692.97 |
DisclosureSEC source: 0001748691-26-000002 · wk-form4_1772661447.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,811 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 14:23 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRSUs (Restricted Stock Units) · Derivative | 152 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000011 · form4.xml · derivative · entry 2 Kaye Mark · CIK 0001748691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 152 shares Expires 2035-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 100% after a one year period with the RSU vesting immediately upon termination of the Director's service. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 14:23 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 152 | $0.00 | $0.00 |
DisclosureSEC source: 0000816956-26-000011 · form4.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:17 UTC | Elevance Health, Inc. ELV · Entity 2934 | Tax withholdingCommon Stock | 2,895 | $340.24 | $984,994.80 |
DisclosureSEC source: 0001748691-25-000007 · wk-form4_1759522630.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,082 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:41 UTC | CONMED Corp CNMD · Entity 4691 | GrantRSUs (Restricted Stock Units) · Derivative | 668 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-016769 · form4.xml · derivative · entry 2 Kaye Mark · CIK 0001748691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 668 Underlying: Common Stock · 668 shares Expires 2035-06-02 F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2025 Long-Term Incentive Plan, with the RSUs generally vesting 100% after a one year period with the RSU vesting immediately upon termination of the Director's service. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:41 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 8,061 | $0.00 Strike: $55.38 | $0.00 |
DisclosureSEC source: 0001127602-25-016769 · form4.xml · derivative · entry 1 Kaye Mark · CIK 0001748691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,061 Underlying: Common Stock · 8,061 shares Expires 2035-06-02 F1 · derivative.exercise_date: The stock options were granted under the Company's 2025 Long-Term Incentive Plan and generally vest 100% after a one year period. Read SEC document |
| April 24, 2025 Filed Apr 25, 2025 20:17 UTC | Elevance Health, Inc. ELV · Entity 2934 | SaleCommon Stock | 4,588 | $424.82 | $1,949,074.16 |
DisclosureSEC source: 0001156039-25-000060 · wk-form4_1745612235.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,977 F1 · price: This transaction was executed in multiple trades, each at the same price of $424.82. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:44 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantEmployee Stock Option (Right to Buy) · Derivative | 13,713 | $0.00 Strike: $395.50 | $0.00 |
DisclosureSEC source: 0001156039-25-000024 · wk-form4_1741211054.xml · derivative · entry 3 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,713 Underlying: Common Stock · 13,713 shares Expires 2035-03-03 F4 · derivative.exercise_date: The option represents a right to purchase a total of 13,713 shares, and is exercisable in three annual installments of 4,571 shares each, beginning on 3/3/2026, which is the one-year anniversary of the option grant date. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:44 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 3,604 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-25-000024 · wk-form4_1741211054.xml · nonDerivative · entry 2 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,565 F2 · shares: Represents restricted share units. Restrictions lapse as follows:1,201 shares each on 3/3/2026 and 3/3/2027, and 1,202 shares on 3/3/2028. F3 · balance_after: Balance includes 17.59 shares acquired on December 20, 2024 through a dividend reinvestment plan. Read SEC document |
| March 03, 2025 Filed Mar 5, 2025 21:44 UTC | Elevance Health, Inc. ELV · Entity 2934 | Tax withholdingCommon Stock | 270 | $395.50 | $106,785.00 |
DisclosureSEC source: 0001156039-25-000024 · wk-form4_1741211054.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,961 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 14:33 UTC | CONMED Corp CNMD · Entity 4691 | GrantRSUs (Restricted Stock Units) · Derivative | 152 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-006784 · form4.xml · derivative · entry 2 Kaye Mark · CIK 0001748691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152 Underlying: Common Stock · 152 shares Expires 2035-02-24 F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan, with the RSUs generally vesting 100% after a one year period. Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 14:33 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 1,846 | $0.00 Strike: $61.97 | $0.00 |
DisclosureSEC source: 0001127602-25-006784 · form4.xml · derivative · entry 1 Kaye Mark · CIK 0001748691 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,846 Underlying: Common Stock · 1,846 shares Expires 2035-02-24 F1 · derivative.exercise_date: The stock options were granted under the Company's 2020 Amended and Restated Non-Employee Director Equity Compensation Plan and generally vest 100% after a one year period. Read SEC document |
| October 02, 2024 Filed Oct 4, 2024 20:35 UTC | Elevance Health, Inc. ELV · Entity 2934 | Tax withholdingCommon Stock | 2,818 | $505.16 | $1,423,540.88 |
DisclosureSEC source: 0001156039-24-000115 · wk-form4_1728074148.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,213 F1 · shares: PAYMENT OF TAX LIABILITY BY WITHHOLDING STOCK INCIDENT TO THE VESTING OF PREVIOUSLY GRANTED RESTRICTED STOCK. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:22 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantEmployee Stock Option (Right to Buy) · Derivative | 10,633 | $0.00 Strike: $499.11 | $0.00 |
DisclosureSEC source: 0001156039-24-000027 · wk-form4_1709673760.xml · derivative · entry 2 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,633 Underlying: Common Stock · 10,633 shares Expires 2034-03-01 F2 · derivative.exercise_date: The option represents a right to purchase a total of 10,633 shares, and is exercisable in two installments of 3,544 shares each, and one installment of 3,545 shares, beginning on 3/1/2025, which is the one-year anniversary of the option grant date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:22 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 2,755 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-24-000027 · wk-form4_1709673760.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,031 F1 · shares: Represents restricted share units. Restrictions lapse as follows: 918 shares each on 3/1/2025 and 3/1/2026 and 919 shares on 3/1/2027. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:22 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantEmployee Stock Option (Right to Buy) · Derivative | 8,076 | $0.00 Strike: $440.19 | $0.00 |
DisclosureSEC source: 0001156039-23-000104 · wk-form4_1696450904.xml · derivative · entry 3 Kaye Mark · CIK 0001748691 · EVP & CFO Designate 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,076 Underlying: Common Stock · 8,076 shares Expires 2033-10-02 F3 · derivative.exercise_date: The option represents a right to purchase a total of 8,076 shares, and is exercisable in three annual installments of 2,692 shares each, beginning on 10/2/2024, which is the one-year anniversary of the option grant date. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:22 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 2,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-23-000104 · wk-form4_1696450904.xml · nonDerivative · entry 2 Kaye Mark · CIK 0001748691 · EVP & CFO Designate 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,276 F2 · shares: Represents restricted share units. Restrictions lapse as follows: 700 shares on 10/2/2024 and 701 shares each on 10/2/2025 and 10/2/2026. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:22 UTC | Elevance Health, Inc. ELV · Entity 2934 | GrantCommon Stock | 18,174 | $0.00 | $0.00 |
DisclosureSEC source: 0001156039-23-000104 · wk-form4_1696450904.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & CFO Designate 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,174 F1 · shares: Represents restricted share units. Restrictions lapse as follows: 6,058 shares each on 10/2/2024, 10/2/2025 and 10/2/2026. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,544 | $0.00 Strike: $325.99 | $0.00 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · derivative · entry 16 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,544 shares Expires 2032-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,857 | $0.00 Strike: $276.84 | $0.00 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · derivative · entry 15 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,857 shares Expires 2031-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 714 | $0.00 Strike: $277.05 | $0.00 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · derivative · entry 14 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 714 shares Expires 2030-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,470 | $0.00 Strike: $280.42 | $0.00 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · derivative · entry 13 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,470 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,741 | $0.00 Strike: $173.58 | $0.00 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · derivative · entry 12 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,741 shares Expires 2029-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | SaleCommon Stock | 1,544 | $340.89 | $526,334.16 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 11 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,447 Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionCommon Stock | 1,544 | $325.99 | $503,328.56 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 10 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | SaleCommon Stock | 3,857 | $340.81 | $1,314,519.98 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 9 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,447 F4 · price: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $340.8001 - $340.990. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionCommon Stock | 3,857 | $276.84 | $1,067,771.88 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 8 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,304 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | SaleCommon Stock | 714 | $341.04 | $243,502.56 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 7 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,447 Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionCommon Stock | 714 | $277.05 | $197,813.70 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 6 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | SaleCommon Stock | 3,470 | $340.88 | $1,182,855.34 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 5 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,447 F3 · price: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $340.8701 - $341.060. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionCommon Stock | 3,470 | $280.42 | $973,057.40 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 4 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | SaleCommon Stock | 1,741 | $341.22 | $594,058.45 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 3 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,447 F2 · price: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $341.170 - $341.280. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionCommon Stock | 1,741 | $173.58 | $302,202.78 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 2 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,188 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 07, 2023 Filed Aug 8, 2023 21:59 UTC | MOODYS CORP /DE/ MCO · Entity 386 | SaleCommon Stock | 3,832 | $341.10 | $1,307,097.50 |
DisclosureSEC source: 0001059556-23-000056 · wk-form4_1691531951.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,447 F1 · price: The price reported in Column 4 is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $341.080 - $341.195. The Reporting Person will provide upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 20:00 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Tax withholdingCommon Stock | 43 | $344.19 | $14,800.17 |
DisclosureSEC source: 0001209191-23-040936 · doc4.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,279 F1 · shares: Disposition of shares to satisfy tax withholding obligation. Read SEC document |
| May 19, 2023 Filed May 22, 2023 20:00 UTC | MOODYS CORP /DE/ MCO · Entity 386 | SaleCommon Stock | 975 | $317.91 | $309,962.25 |
DisclosureSEC source: 0001209191-23-031405 · doc4.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,322 F1 · kind: Sale of shares pursuant to Rule 10b5-1 Plan. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:01 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Tax withholdingCommon Stock | 3,426 | $290.63 | $995,698.38 |
DisclosureSEC source: 0001209191-23-015386 · doc4.xml · nonDerivative · entry 2 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,297 F2 · shares: Disposition of shares to satisfy tax withholding obligation. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:01 UTC | MOODYS CORP /DE/ MCO · Entity 386 | GrantCommon Stock | 5,537 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-015386 · doc4.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,723 F1 · shares: Receipt of shares acquired upon settlement of 2020-2022 Performance Shares. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:00 UTC | MOODYS CORP /DE/ MCO · Entity 386 | GrantEmployee Stock Option (right to buy) · Derivative | 5,757 | $0.00 Strike: $295.33 | $0.00 |
DisclosureSEC source: 0001209191-23-012249 · doc4.xml · derivative · entry 2 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,757 Underlying: Common Stock · 5,757 shares Expires 2033-02-21 F2 · derivative.exercise_date: One fourth of options vest each year beginning with the date indicated. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:00 UTC | MOODYS CORP /DE/ MCO · Entity 386 | GrantCommon Stock | 1,845 | $295.33 | $544,883.85 |
DisclosureSEC source: 0001209191-23-012249 · doc4.xml · nonDerivative · entry 1 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,186 F1 · shares: Exempt grant of restricted stock units. Read SEC document |
| August 15, 2022 Filed Aug 16, 2022 20:00 UTC | MOODYS CORP /DE/ MCO · Entity 386 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,740 | $0.00 Strike: $173.58 | $0.00 |
DisclosureSEC source: 0001209191-22-045963 · doc4.xml · derivative · entry 6 Kaye Mark · CIK 0001748691 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,740 shares Expires 2029-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Exercise and sale of shares pursuant to Rule 10b5-1 Plan. F2 · derivative.exercise_date: One fourth of options vest each year beginning with the date indicated. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.